麓鹏制药拟港股上市 中国证监会要求补充说明搭建离岸架构及返程并购的合规性等事项

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional compliance information from LUPENG Pharmaceutical regarding its offshore structure and reverse mergers as part of its listing application on the Hong Kong Stock Exchange [1][2]. Group 1: Compliance and Regulatory Requirements - LUPENG Pharmaceutical is required to clarify the compliance of its offshore structure and reverse investment, including details on foreign exchange management, overseas investment, foreign investment, and tax management [1]. - The company must provide a legal opinion on the pricing basis, payment methods, and tax obligations related to the acquisition of its domestic operating entity [2]. - The CSRC has requested a thorough examination of the company's stockholder structure, including the transparency of major shareholders and the rationale behind recent share prices [2]. Group 2: Corporate Structure and Operations - The company must disclose the registered capital and actual contributions of its domestic operating entity, as well as the legality of past capital increases and share transfers [3]. - Updates on the regulatory compliance status of LUPENG's domestic entity, specifically regarding its operational scope and necessary licenses, are required [3]. - The company is also asked to outline its plans for share splitting and the expected fundraising amounts, including the allocation of funds for domestic and international purposes [3]. Group 3: Product and Market Position - LUPENG Pharmaceutical is recognized as a leading global biopharmaceutical company with a proprietary drug development platform focused on high bioavailability oral medications for cancer and autoimmune diseases [4]. - The company's core product, LP-168, is a dual BTK inhibitor currently in the NDA stage, showing significant clinical benefits and safety advantages over traditional BTK inhibitors [4].